EUVIMEDEUVIMED entdecken
Crossref

The Veterans Affairs Pentoxifylline in Diabetic Kidney Disease (VA PTXRx) Study: Baseline Characteristics

David J Leehey iD, Rajiv Agarwal iD, Bin Xing, Christina Clise, Sankar Navaneethan, Kristina Utzschneider, Douglas Lammie, Yongliang Wei, Jeffrey Huminik, Linda Polzin, Blake Glomb, Kimberly Carlson

Nephrology Dialysis Transplantation · 22.10.2026

DOI: 10.1093/ndt/gfag245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 22.10.2026. Verfasst von David J Leehey und 11 weiteren Autor:innen. Beteiligte Einrichtung: Edward Hines, Jr. VA Medical Center, Hines, IL, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Experimental and clinical data suggest that the non-specific phosphodiesterase inhibitor pentoxifylline (PTX) reduces proteinuria and may delay the progression of diabetic kidney disease (DKD). However, no large-scale randomized clinical trial has determined whether PTX can reduce end-stage kidney disease (ESKD) and mortality in DKD.

Design

VA PTXRx is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to test the hypothesis that PTX, when added to usual care, prolongs the time to kidney failure or death in type 2 diabetic (T2D) participants with DKD compared to usual care plus placebo. Enrolled participants at very high risk for ESKD and/or death were randomized in a 1:1 ratio to either PTX 400 mg twice daily or matching placebo using randomly permuted blocks with stratification for site, renin-angiotensin-aldosterone (RAAS) inhibitor use, and chronic kidney disease (CKD) stage. The study is event-driven, requiring 646 primary events (ESKD (chronic dialysis or transplantation) or death) to achieve 80% power to detect a relative risk reduction of 19% with PTX. Baseline Results Between December 2019 and November 2025, 2376 participants at 34 VA sites in the USA were randomized. The mean age at randomization was 72.3 years (SD 7.7), with 97% being male. The mean baseline eGFR was 33.3 mL/min/1.73 m2 (SD 9.4). The median urinary albumin to creatinine ratio (UACR) was 401 mg/g (IQR 122-1076). At baseline, the usage of RAAS inhibitors was 80.0%, sodium-glucose transporter-2 (SGLT2) inhibitors 52.9%, glucagon-like peptide-1 (GLP-1) receptor agonists 33.2%, and finerenone 3.0%. The majority (88%) of participants had stage 3B or 4 CKD (eGFR < 45 mL/min/1.73m2).

Conclusions

The results, anticipated in 2027, are expected to determine whether PTX is a treatment option for patients with high-risk DKD. Because PTX is a generic medication, it is inexpensive in many health systems, which would facilitate access if it proves effective. Trial Registration: This study is registered with clinicaltrials.gov (Identifier: NCT03625648).

Schlagwörter

Stichwörter der Autor:innen

CKDESKDalbuminuriadiabetic kidney diseasepentoxifylline

Autor:innen und Institutionen

  • Edward Hines, Jr. VA Medical Center, Hines, IL, USA.
  • Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA.
  • VA Cooperative Studies Program Coordinating Center, Hines, IL, USA.
  • VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, USA.
  • Michael E. DeBakey VA Medical Center, Houston, TX, USA.
  • VA Puget Sound Health Care System, Seattle, WA, USA.

ORCID-Profile: David J Leehey, Rajiv Agarwal

Zitieren

APA

Leehey, D. J., Agarwal, R., Xing, B., Clise, C., Navaneethan, S., Utzschneider, K., Lammie, D., Wei, Y., Huminik, J., Polzin, L., Glomb, B., & Carlson, K. (2026). The Veterans Affairs Pentoxifylline in Diabetic Kidney Disease (VA PTXRx) Study: Baseline Characteristics. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag245

Vancouver

Leehey DJ, Agarwal R, Xing B, Clise C, Navaneethan S, Utzschneider K, et al. The Veterans Affairs Pentoxifylline in Diabetic Kidney Disease (VA PTXRx) Study: Baseline Characteristics. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag245

BibTeX
@article{Leehey2026,
  author = {Leehey, David J and Agarwal, Rajiv and Xing, Bin and Clise, Christina and Navaneethan, Sankar and Utzschneider, Kristina and Lammie, Douglas and Wei, Yongliang and Huminik, Jeffrey and Polzin, Linda and Glomb, Blake and Carlson, Kimberly},
  title = {The Veterans Affairs Pentoxifylline in Diabetic Kidney Disease (VA PTXRx) Study: Baseline Characteristics},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag245}
}
Kostenlos starten →